Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non–small cell lung cancer.
Sukhmani Padda, MD
Advertisement
Articles by Sukhmani Padda, MD
Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.
Advertisement
Latest Updated Articles
Exploring Advantages to Third-Generation TKIs in Lung CancerPublished: February 1st 2019 | Updated:
Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung CancerPublished: March 26th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
